An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: The pediatric brain tumor consortium phase I experience

Clinical and Translational Science

Volumn 2, Issue 2, 2009, Pages 143-149

  Onar, Arzu ^a   Ramamurthy, Uma ^a   Wallace, Dana ^a   Boyett, James M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Computing and operational infrastructure; Early phase clinical trials; Paperless data acquisition and management; Pediatric oncology

Indexed keywords

6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; BUSULFAN; CAPECITABINE; CEDIRANIB; CILENGITIDE; CLORETAZINE; ENZASTAURIN; GEFITINIB; IMATINIB; LAPATINIB; LENALIDOMIDE; LONAFARNIB; MK 0752; SEMAXANIB; SPARTAJECT; TEMOZOLOMIDE; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BODY SURFACE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD CARE; CLINICAL RESEARCH; CLINICAL TRIAL; COMMUNICATION PROTOCOL; COMPUTER PROGRAM; DOSE CALCULATION; DRUG DOSE ESCALATION; HUMAN; INFORMATION PROCESSING; INTERNET; MEDICAL RESEARCH; NEUROIMAGING; PRIORITY JOURNAL; QUALITY CONTROL; BIOSTATISTICS; BRAIN NEOPLASMS; CHILD; COOPERATION; DATA BASE; DIAGNOSTIC IMAGING; DOSE RESPONSE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; TELECOMMUNICATION;

BIOSTATISTICS; BRAIN NEOPLASMS; CHILD; CLINICAL TRIALS, PHASE I AS TOPIC; COOPERATIVE BEHAVIOR; DATABASE MANAGEMENT SYSTEMS; DIAGNOSTIC IMAGING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PATIENT SELECTION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TELECOMMUNICATIONS;

EID: 77950860355     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2009.00105.x     Document Type: Article

References (12)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase I clinical studies in cancer. Biometrics. 1990; 46: 33-48.
2. Onar A, Kocak M, Boyett JM. Modified continual reassessment method versus the traditional empirically based design for phase I trials in pediatric oncology: Experiences of the Pediatric Brain Tumor Consortium. J Biopharm Stat. In press, 2009.
3. Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowitz M, Hunt D, Kieran M, Kun L, Packer R, Phillips P, Pollack IF, Prados M, Heideman R. Phase I clinical trial of mafosfamide in infants and children age 3 years or younger with newly diagnosed embryonal tumors: A Pediatric Brain Tumor Consortium study (PBTC-001). J Clinical Oncol. 2005; 23(3): 525-531.
4. Kieran MW, Supko JG, Wallace D, Fruscio R, Young-Poussaint T, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Prados M, Geyer R, Friedman H, Goldman S, Kun LE, MacDonald, T. A Pediatric Brain Tumor Consortium phase I study of SU5416 in pediatric brain tumors. Ped Blood Cancer. 2009; 52(2): 169-176.
5. Kieran M, Packer R, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor Sarasar™ (Lonafarnib-SCH66336) given twice daily to pediatric patients with advanced central nervous system tumors: A Pediatric Brain Tumor Consortium (PBTC) study. J Clinical Oncol. 2007; 25(21): 3137-3143.
6. Gururangan S, Petros WP, Young-Poussaint T, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal Spartaject™ Busulfan in children with neoplastic meningitis-A Pediatric Brain Tumor Consortium study (PBTC-004). Clin Cancer Res. 2006; 12(5): 1540-1546.
7. Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A. Phase I trial offsingle-dose temo-zolomide and continuous administration of O6-benzylguanine in children with brain tumors: A Pediatric Brain Tumor Consortium report. Clin Cancer Res. 2007; 13(22): 6712-6718.
8. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer RJ, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malig-nant gliomas: A Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007; 9(2): 145-160.
9. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE. Phase I Clinical Trial of Cilengitide (EMD 121974) in children with refractory brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-012). J Clin Oncol. 2008; 26(6): 919-924.
10. Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer RJ, Fouladi M, McKnight T, Young-Poussaint T, Broniscer A, Blaney SM, Boyett JM, Kun LE. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem Gliomas. Neuro Oncol. 2008; 10(3): 341-347.
11. Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer RJ, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE. Phase I trial of VNP40101M (CLORETAZINE ®) in children with recurrent brain tumors-a Pediatric Brain Tumor Consortium (PBTC) study. Clin Cancer Res. 2008; 14(4): 1124-1130.
12. Anderson BD, Adamson PC, Weiner SL, McCabe MS, Smith MA. Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives. J Clin Oncol. 2004; 22: 4846-4850.